Table 1.
Baseline characteristics
| PCI group, (N = 256) | CABG group, (N = 227) | p value | |
|---|---|---|---|
| Age | 72.7 ± 5.3 | 72.7 ± 5.1 | 0.9 |
| Male, n (%) | 200 (78.1) | 155 (68.3) | 0.017 |
| BMI, kg/m2 | 24.0 ± 3.3 | 23.8 ± 3.4 | 0.7 |
| Hypertension, n (%) | 197 (77.0) | 168 (74.0) | 0.45 |
| Dyslipidemia, n (%) | 196 (76.6) | 156 (68.7) | 0.053 |
| Smoking, n (%) | 180 (58.6) | 142 (62.6) | 0.2 |
| Family history, n (%) | 71 (27.7) | 40 (17.6) | 0.008 |
| Hemodialysis, n (%) | 19 (7.4) | 3 (1.3) | 0.0013 |
| Prior MI, n (%) | 76 (29.8) | 101 (44.5) | 0.0019 |
| Total cholesterol, mg/dL | 182.8 ± 31.7 | 179.0 ± 39.3 | 0.2 |
| LDL-C, mg/dL | 111.2 ± 26.4 | 106.4 ± 27.9 | 0.055 |
| HDL-C, mg/dL | 44.9 ± 13.1 | 46.0 ± 13.0 | 0.36 |
| Triglyceride, mg/dL | 134.0 ± 73.5 | 133.3 ± 66.7 | 0.9 |
| HbA1c (NGSP), % | 7.0 ± 1.1 | 7.3 ± 1.1 | 0.015 |
| LVEF, % | 61.9 ± 11.5 | 56.7 ± 12.9 | <0.001 |
| eGFR, mL/min/1.73 m2 | 64.1 ± 25.0 | 60.3 ± 27.3 | 0.1 |
| Medication, (%) | |||
| Aspirin | 97.7 | 93.8 | 0.08 |
| Dual antiplatelet therapy | 97.7 | 15.3 | <0.0001 |
| Statin | 69.8 | 23.7 | <0.0001 |
| ACE-I/ARB | 51.4 | 28.7 | <0.0001 |
| β-blocker | 51.4 | 33.2 | <0.0001 |
| Diseased vessel, (%) | |||
| Triple-vessel disease, (%) | 53.5 | 74.0 | <0.0001 |
| Left main trunk, (%) | 19.6 | 37.4 | 0.0002 |
| Left internal thoracic artery, (%) | NA | 223 (98.2) | NA |
| Bilateral internal thoracic artery, (%) | NA | 127 (55.9) | NA |
| Total arterial revascularization, (%) | NA | 60 (26.4) | NA |
| Type of coronary artery disease | 0.0005 | ||
| Stable angina pectoris | 88.3 | 76.2 | |
| Acute coronary syndrome | 11.7 | 23.8 | |
NA not applicable, BMI body mass index, MI myocardial infarction, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, HbA1c glycated hemoglobin, LVEF left ventricular ejection fraction, eGFR estimated glomerular filtration rate, ACE-I angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker